Skip to main content
. 2021 May 6;2(5):e250–e262. doi: 10.1016/S2666-7568(21)00062-3

Table 1.

Phase 2b patient demographics at baseline (full analysis set)

Study part 1
Study part 2
RTB101 5 mg (n=61) RTB101 10 mg once daily (n=58) Placebo (n=60) Overall (n=179) RTB101 10 mg once daily (n=118) RTB101 10 mg twice daily (n=120) RTB101 plus everolimus (n=115) Placebo (n=120) Overall (n=473)
Age at randomisation, years
Mean (SD) 74·0 (8·2) 76·5 (7·9) 74·4 (7·3) 74·9 (7·9) 73·1 (6·9) 73·0 (6·9) 73·9 (7·0) 73·2 (7·2) 73·3 (7·0)
Median (IQR) 71·0 (68·0–79·0) 76·0 (69·0–82·0) 72·0 (69·0–79·0) 72·0 (69·0–80·0) 71·0 (68·0–77·0) 71·0 (67·5–78·0) 73·0 (68·0–78·0) 71·0 (68·0–77·0) 71·0 (68·0–78·0)
Sex
Male 33 (54%) 31 (53)% 36 (60%) 100 (56%) 52 (44%) 61 (501%) 57 (50%) 53 (44%) 223 (47%)
Female 28 (46%) 27 (47%) 24 (40%) 79 (44%) 66 (56%) 59 (49%) 58 (50%) 67 (56%) 250 (53%)
Race
White 56 (92%) 54 (93%) 57 (95%) 167 (93%) 114 (97%) 110 (91%) 106 (92%) 109 (91%) 439 (93%)
Black or African American 0 0 0 0 4 (3%) 9 (8%) 5 (4%) 10 (8%) 28 (6%)
Native Hawaiian or other Pacific Islander 2 (3%) 2 (3%) 2 (3%) 6 (3%) 0 0 0 0 0
Other 1 (2%) 0 1 (1·7%) 2 (1%) 0 0 2 (1·7%) 1 (<1%) 3 (<1%)
Asian 2 (3%) 2 (3%) 0 4 (2%) 0 0 1 (<1%) 0 1 (<1%)
American Indian or Alaska Native 0 0 0 0 0 1 (<1%) 1 (<1%) 0 2 (<1%)
Ethnicity
Not-Hispanic or Latino 61 (100%) 58 (100%) 60 (100%) 179 (100%) 108 (92%) 114 (95%) 101 (88%) 108 (90%) 431 (91%)
Hispanic or Latino 0 0 0 0 10 (9%) 6 (5%) 14 (12%) 12 (10%) 42 (9%)
BMI at baseline (kg/m2)
Mean (SD) 28·4 (5·1) 30·0 (5·8) 28·6 (5·5) 29·0 (5·5) 30·9 (6·9) 31·2 (6·1) 30·1 (6·8) 30·5 (6·0) 30·7 (6·5)

Data are n (%), unless otherwise specified.